Candel Therapeutics (CADL) Total Liabilities (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Total Liabilities data on file, last reported at $73.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities rose 80.75% year-over-year to $73.3 million; the trailing twelve-month figure through Dec 2025 stood at $73.3 million (up 80.75% YoY), and the FY2025 full-year result was $73.3 million, up 80.75% from the prior year.
• Total Liabilities grew to $73.3 million in Q4 2025, from $13.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $73.3 million in Q4 2025 to a low of $13.5 million in Q3 2025.
• A 5-year average of $31.1 million and a median of $28.5 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 96.09% in 2021 and sank 63.36% in 2025, its largest moves.
• Tracing CADL's Total Liabilities over 5 years: stood at $25.1 million in 2021, then gained by 19.58% to $30.0 million in 2022, then dropped by 5.07% to $28.5 million in 2023, then surged by 42.46% to $40.5 million in 2024, then jumped by 80.75% to $73.3 million in 2025.
• Business Quant data shows CADL's Total Liabilities at $73.3 million in Q4 2025, $13.5 million in Q3 2025, and $15.8 million in Q2 2025.